TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• TScan Therapeutics, Inc. has received a consensus recommendation of "Moderate Buy" from six analysts, with one sell and five buy ratings among them.
• The stock has an average price target of $7.80, while current trading is at approximately $2.48 per share, indicating potential for upside.
• For its last quarter, TScan Therapeutics reported earnings per share of ($0.28) and revenue of $3.08 million, surpassing analyst expectations.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $7.80.

TCRX has been the topic of a number of recent research reports. Wall Street Zen raised TScan Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of TScan Therapeutics in a research report on Wednesday, October 8th. Finally, Wedbush reissued an "outperform" rating and set a $7.00 target price on shares of TScan Therapeutics in a research report on Tuesday, August 12th.

TScan Therapeutics Trading Up 11.2%

Shares of NASDAQ:TCRX opened at $2.48 on Friday. The company has a market cap of $140.74 million, a P/E ratio of -2.28 and a beta of 0.99. The stock's 50-day moving average is $1.87 and its 200-day moving average is $1.65. TScan Therapeutics has a 52-week low of $1.02 and a 52-week high of $6.22. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.06 and a current ratio of 7.06.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). The company had revenue of $3.08 million for the quarter, compared to the consensus estimate of $1.31 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%. Equities research analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On TScan Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Aberdeen Group plc boosted its holdings in TScan Therapeutics by 0.9% during the first quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock valued at $1,230,000 after purchasing an additional 7,744 shares in the last quarter. Boothbay Fund Management LLC boosted its holdings in TScan Therapeutics by 50.0% during the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company's stock valued at $35,000 after purchasing an additional 8,121 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in TScan Therapeutics by 6.0% during the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company's stock valued at $235,000 after purchasing an additional 9,676 shares in the last quarter. Catalyst Funds Management Pty Ltd acquired a new stake in TScan Therapeutics during the second quarter valued at approximately $26,000. Finally, Letko Brosseau & Associates Inc. boosted its holdings in TScan Therapeutics by 24.4% during the second quarter. Letko Brosseau & Associates Inc. now owns 95,875 shares of the company's stock valued at $139,000 after purchasing an additional 18,775 shares in the last quarter. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.